Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Single-dose, Clinical Trial of 68Ga-DOTATATE (GalioMedix™) PET-CT Scan for Diagnosis of Primary and Metastatic Somatostatin Receptor-positive Neuroendocrine Tumors (NETs)

NCT01879657 is registered in ClinicalTrials.gov with Radio Isotope Therapy of America as lead sponsor.

NCT NCT01879657
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01879657 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Single-dose, Clinical Trial of 68Ga-DOTATATE (GalioMedix™) PET-CT Scan for Diagnosis of Primary and Metastatic Somatostatin Receptor-positive Neuroendocrine Tumors (NETs)
Lead sponsor
Radio Isotope Therapy of America
Phase
Not applicable
Overall status
Completed
Start date
March 1, 2013
Completion date
December 5, 2017
Enrollment
169 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

neuroendocrine carcinoma